Choroidal Neovascular Membranes

Back

Background

Choroidal neovascular membranes (CNVMs) are associated with many diseases. The most common causes are age-related macular degeneration (AMD),[1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26] presumed ocular histoplasmosis syndrome (POHS),[27] myopic macular degeneration,[28] trauma, and angioid streaks; however, many cases are idiopathic.

The natural history of patients with AMD should not be overlooked when pilot studies of new therapies are reported. In a randomized trial (of 481 patients) of interferon alpha-2, 62% of the placebo group stabilized at 1 year, losing less than 3 lines of vision. Randomized clinical trials are necessary in assessing treatment efficacy in cases of CNVM secondary to AMD as well as other causes. Submacular surgery, photodynamic therapy, translocation, and transpupillary thermotherapy (TTT) were once advocated as a means of stabilizing vision, where stable is defined a modest reduction in the rate of vision loss. True stabilization should be defined as no visual loss. A therapy that purports to stabilize vision requires large numbers of patients in a randomized trial with long-term follow-up to prove stabilization.

Clinical trials of ranibizumab not only showed true stabilization in approximately 75% of cases (ie, avoidance of 3 lines [15 ETDRS letters] of visual loss [defined as moderate visual loss]) but also 30-40% of patients had visual improvement.

Subfoveal CNVMs do not result in a loss of ambulatory vision if untreated. The natural history of subfoveal CNVMs never results in total blindness, while this outcome is all too frequent with macular translocation and occasionally with submacular surgery.[29]

Pathophysiology

CNVMs may be thought of as the initial phase of a choroidal scar. Because these structures angiographically demonstrate a network of vessels, they are often referred to as "nets." The early phase of these lesions is termed exudative, while the later phase is termed cicatricial. Increased permeability of new vessels to fluorescein and indocyanine green (ICG) creates the familiar angiographic appearance referred to as "leakage."

Vascular endothelial growth factor (VEGF) is present during the neovascularization phase. Because the scars are often circular in nature, they are called disciform scars when they enter the cicatricial phase. CNVMs, like all scarring disorders, seem to be a repair process with tissue loss or damage initiating the repair activity. The cause of tissue destruction in AMD is probably apoptosis, programmed cellular death. POHS, trauma, laser therapy, and angioid streaks all have in common a defect in the retinal pigment epithelium (RPE) and/or choriocapillaris.[30, 11, 31, 32, 33] Genetic abnormalities, specifically single polynucleotide polymorphism in the alternative complement pathway and reactive oxygen species, play a specific role in AMD.

Epidemiology

Frequency

United States

The overall prevalence of neovascular AMD in people older than 40 years is estimated to be 1.47%. The prevalence increases with advancing age. Patients in their 70s are more likely to have AMD than patients in their 60s, and patients in their 80s are more likely to have wet AMD than patients in their 70s.[34, 35]

International

Polypoidal choroidal vasculopathy, which is a risk factor for CNVMs, is more common in Asian patients than in white patients.[36]

Myopia, which is also a risk factor for CNVMs, is more common in Asian patients than in white patients or black patients.

Mortality/Morbidity

CNVM and most related diseases are not characterized by increased mortality rates. Smoking increases the progression rate of AMD by 350-500%, and, of course, smoking dramatically increases cancer and cardiovascular death rates. Morbidity is limited to the loss of central vision; the peripheral vision is virtually always retained in cases of CNVM unless complications of surgical therapy occur.

Race

The incidence rate of AMD is less in blacks than in whites (see Age).

Other causes of CNVMs are not associated with differences in racial incidence, except for angioid streaks associated with sickle cell disease and ethnic differences in the incidence of myopia.

Sex

Ocular trauma is more common in men than in women and is a known cause of CNVMs. AMD is slightly more common in women than in men. No known significant sexual predilection exists for other causes of CNVMs.

Age

The prevalence of AMD increases rapidly with age.[22]

AMD is more common after age 60 years, with the frequency increasing for patients in their 70s and an even greater frequency for patients in their 80s. The frequency of AMD is 11.90% in white men older than 80 years and 16.39% in white women older than 80 years.

Histoplasmosis typically occurs in the 30s or 40s.

Angioid streaks occur in individuals aged 30-60 years.

Myopic macular degeneration typically occurs after age 25 years.

Prognosis

Early diagnosis and immediate intervention with anti-VEGF therapy are crucial to improving outcomes. The prognosis of all CNVMs is very good, regardless of cause, if anti-VEGF therapy is initiated before bleeding or scarring occurs. Many patients with AMD require treatment for many years. In general, patients who receive more injections have better outcomes. No known adverse events are associated with anti-VEGF therapy.

Patients treated with a monthly (31-42 days, no longer) regimen or treat-and-extend approach (preferred practice pattern) have a better prognosis than patients treated using a PRN strategy (ie, treatment administered only when subretinal fluid or intraretinal fluid is noted on optical coherence tomography [OCT] imaging).

Patient Education

Teaching patients to use the Amsler grid, reading text and other home testing schemes daily, is essential to improving outcomes. Patients should be instructed to contact their eye physician immediately if any visual disturbance occurs; it should not be limited to a scripted definition of "distortion." Office staff should be instructed that these patients should be seen within a few days and undergo OCT imaging and clinical examination.

History

Patients with choroidal neovascular membranes (CNVMs) may report the following:[37, 38]

Physical

Perform an examination using a slit lamp biomicroscopy and a fundus contact lens or 60-, 78-, or 90-diopter (D) lens. Fluorescein angiography (FA) is required in some cases. ICG angiography is useful in approximately 5-10% of cases. Optical coherence tomography (OCT) has become an essential part in the assessment of these patients.

Clinical findings

Grey or ill-defined CNVMs can be subfoveal, juxtafoveal, extrafoveal, peripapillary, or even in the periphery. Experienced observers often visualize these lesions without OCT imaging or angiography, although imaging is necessary in virtually all instances.[39, 40] OCT imaging has largely replaced angiography.

Subretinal hemorrhage is common and frequently outlines the CNVM. In some cases, very large choroidal and/or subretinal hemorrhages occur that can be mistaken for malignant melanomas of the choroid.

Exudate, serous fluid, or both are often present with choroidal neovascularization (CNV). Angiographically well-defined membranes are referred to as classic; these lesions are usually subretinal. In many cases, the neovascular membrane is ill-defined and is termed occult; these lesions are usually under the retinal pigment epithelium (RPE) and often associated with a pigment epithelial detachment (PED). Retinal angiomatous proliferation (RAP) can be seen clinically; the neovascularization is now thought to arise from the choroid. Polypoidal choroidal vasculopathy is virtually impossible to identify clinically but can be accompanied by exudate, subretinal fluid, and hemorrhage. Large amounts of subretinal blood, fluid, or exudate may prevent clinical or angiographic visualization of the underlying CNV.

Causes

AMD, POHS, myopia, trauma, angioid streaks, certain hereditary macular degenerations, and other causes of macular RPE damage have been associated with CNVM formation. Many cases are idiopathic.

Laboratory Studies

No laboratory tests exist for most diseases associated with choroidal neovascular membranes (CNVMs).

Hereditary macular degeneration can usually be identified from clinical presentation, family history, angiography, electroretinogram (ERG),[41] electro-oculogram (EOG),[42] psychophysical testing (eg, color vision, perimetry, dark adaptation), and genetic testing.

The diagnosis of histoplasmosis is based on fundus findings not serologic or skin testing.

Angioid streaks are usually due to pseudoxanthoma elasticum (PXE), but they have also been reported in patients with sickle cell disease and Paget disease.

Imaging Studies

FA and ICG angiography were historically used in confirming the diagnosis, in determining the efficacy of treatment, in determining the need for retreatment, and, rarely, in guiding laser and photodynamic therapy (PDT).[43, 44, 45, 46, 47, 48, 49] However, OCT imaging has largely replaced angiography.

Digital angiography offers the advantages of immediate viewing, local area network (LAN) and/or wide area network (WAN) access, archiving, and incorporation into the computerized medical record, but it offers no better resolution than film-based imaging. Confocal laser scanning-based imaging dramatically improves the signal to background ratio by 15 dB, provides better illumination of the fluorophore, and improves image quality as compared to a fundus camera-based digital imaging system.

ICG angiography is rarely needed. Retinal angiomatous proliferation (RAP) is relatively common and is best visualized with confocal angiography; however, careful contact lens examination is often sufficient.

Ocular coherence tomography has become an essential tool both in performing the initial workup and in determining the need for treatment and retreatment of patients with CNVMs.[50] The initial technology was based on time domain OCT (Zeiss Stratus III), which served the vitreoretinal community well; however, the recent transition to spectral domain OCT provides far better axial and lateral resolution.[51] It is routinely possible to identify the CNVM, not just the presence of subretinal fluid, PED, and overlying retinal edema. Swept source OCT imaging may prove to be somewhat better than spectral domain OCT imaging. OCT angiography has not been shown to be of value, although there is substantial marketing pressure.

Histologic Findings

Biopsy is not performed in CNVM cases. If submacular surgery is performed for non-AMD cases in very rare instances, histology is not needed, as many of these lesions have been studied; histology is of no value to the patient.[52, 53]

Medical Care

Zinc/antioxidant therapy

In the Age-Related Eye Disease Study (AREDS), zinc combined with other antioxidants has been shown to reduce the progression rate of AMD by approximately 25% in patients with intermediate drusen.[54]

Intravitreal injection

Ranibizumab (Lucentis) is an anti-VEGF monoclonal antibody fragment. Intravitreal ranibizumab is safe and effective in stabilizing and improving vision in patients with choroidal neovascularization (CNV) caused by pathological myopia with a low number of injections.[55] The US Food and Drug Administration (FDA)-approved dose of ranibizumab is 0.5 mg (0.05 mL) administered by intravitreal injection[56, 57] for exudative AMD.

In pivotal Phase III clinical trials involving treatment of neovascular age-related macular degeneration (AMD), ranibizumab was administered once a month for up to 2 years.[58, 59, 60] The benefits of treatment with ranibizumab were also maintained in most patients for up to 2 years with continuous use. Treatment should be continued and monitored. Individual results may vary. In the pivotal clinical trials, some patients reported an improvement in vision starting at day 7 after treatment with ranibizumab. However, just because a patient does not report an immediate improvement, it does not mean that ranibizumab is not working. Some patients experience improvements later or merely do not lose significant vision with ranibizumab.

Compared to continual monthly dosing, dosing every 3 months will lead to an approximate 5-letter (1-line) loss of visual acuity benefit, on average, over the following 9 months. Patients should be evaluated regularly according to the package label.

Monthly injections were used in the pivotal clinical trials, but many retinal specialists have switched to a treat-and-extend paradigm primarily using OCT evidence of subretinal fluid and/or retinal edema as an indication for retreatment. Because of the concern that recurrences occasionally result in poor outcomes, most retinal specialists now use a treat-and-extend strategy; injections are given after leakage is eliminated, and the follow-up interval is extended to 6 weeks. If the lesion is dry at 6 weeks, another injection is given, and the follow-up interval is extended to 8 weeks.

Ranibizumab sets a new standard in the treatment of neovascular AMD because it is the first therapy proven to improve vision instead of simply slowing the decline of central vision loss. In clinical trials, up to 40% of patients gained 15 or more letters of vision and nearly all patients (up to 96%) maintained vision.

Of patients treated with ranibizumab, 94% remained on therapy for 1 year versus 89% of patients in the control groups. Ranibizumab has been studied in more than 1000 patients with neovascular AMD in 2 double-masked, controlled 2-year studies.

Ranibizumab is indicated for the treatment of patients with neovascular (wet) AMD.

Ranibizumab is contraindicated in patients with ocular or periocular infections.

Intravitreal injections, including those with ranibizumab, have been associated with endophthalmitis and retinal detachment.[61] Proper aseptic injection technique should always be used when administering ranibizumab. Patients should be monitored during the week following the injection to permit early treatment, should an infection occur.

Increases in intraocular pressure (IOP) have been noted within 60 minutes of intravitreal injection. IOP and perfusion of the optic nerve head should be monitored and managed appropriately.

Although a low rate (< 4%) of arterial thromboembolic events (ATEs) was observed in one ranibizumab clinical trial, a theoretical risk of ATEs exists following intravitreal use of VEGF inhibitors.

Serious adverse events related to the injection procedure occurring in less than 0.1% of intravitreal injections included endophthalmitis, rhegmatogenous retinal detachment, and iatrogenic traumatic cataract. Other serious ocular events occurring in less than 2% of patients included intraocular inflammation and increased IOP.

In clinical trials, the most common ocular adverse effects included conjunctival hemorrhage, eye pain, and vitreous floaters. The most common nonocular adverse effects included hypertension, nasopharyngitis, headache, and upper respiratory tract infection; none of which have been shown to be related to the drug. Aflibercept (Eylea; VEGF-Trap) is a soluble decoy receptor that binds VEGF and other vascular growth factors. It was approved by the FDA for the treatment of neovascular age-related macular degeneration (AMD) and other CNVs. 

In clinical trials, all aflibercept groups, including one group dosed only every two months, were noninferior and clinically equivalent to monthly ranibizumab for the primary endpoint (the 2q4, 0.5q4, and 2q8 regimens were 95.1%, 95.9%, and 95.1%, respectively, for VIEW 1, and 95.6%, 96.3%, and 95.6%, respectively, for VIEW 2, whereas monthly ranibizumab was 94.4% in both studies). In a prespecified integrated analysis of the 2 studies, all aflibercept regimens were within 0.5 letters of the reference ranibizumab for mean change in best corrected visual acuity (BCVA); all aflibercept regimens also produced similar improvements in anatomic measures. Ocular and systemic adverse events were similar across treatment groups. This led to the labelling of aflibercept for every-2-month administration after loading doses. Some medical retina experts suggest that aflibercept is more effective in patients with pigment epithelial detachments (PED). Clinical trials have shown that aflibercept is often effective in patients in whom ranibizumab or bevacizumab (Avastin) therapy has failed.

Bevacizumab is a larger anti-VEGF monoclonal antibody fragment that was originally developed to treat various types of cancer. Although unapproved by the FDA for treatment of CNV, monotherapy with bevacizumab is very effective and is widely used off-label for CNV not due to wet AMD.

Approximately 50% of retinal specialists use off-label bevacizumab instead of the FDA-approved ranibizumab or aflibercept, using a similar treatment schedule and indications for retreatment. The NEI-sponsored CATT trial was a head-to-head randomized multicenter comparison of ranibizumab to bevacizumab using with both monthly and PRN treatment arms. It revealed essentially no differences in efficacy, with a slightly higher number of adverse effects with bevacizumab.

Technique

Bevacizumab, ranibizumab, and aflibercept are administered through a fine 30- to 31-gauge needle, which most patients tolerate well.

A sterile intravitreal technique using povidone iodine; masks on the patient, tech and injecting physician; and a sterile bladed speculum are essential to reduce the risk of endophthalmitis.

Surgical Care

In 1991, Thomas and Kaplan reported a series of patients operated on for subfoveal CNVMs secondary to POHS.[62] Subsequent series included CNVM associated with AMD, angioid streaks, myopic degeneration, and idiopathic CNVM.[63, 64, 65] Idiopathic cases have the best results, followed by POHS cases. Most studies showed poor results for patients with AMD (approximately 20% had better vision, 60% had the same vision, and 20% had worse vision). Some surgeons state that submacular surgery for CNVM in patients with AMD may result in stabilization. Again, it must be emphasized that this procedure may also result in complete loss of vision, which is not true of the natural course of the disease. Results of the Submacular Surgery Trial (SST) demonstrated that submacular surgery is ineffective in AMD and POHS.

RPE transplantation has been used for patients with AMD by some investigators; 100% of patients undergo rejection of cadaver RPE, requiring immune suppression in those patients without a life-threatening disease.[66] Transplanted RPE cells do not become adherent to the Bruch membrane so the RPE cells would have to be transplanted as a sheet in combination with the Bruch membrane and probably choriocapillaris. Use of nasal RPE and iris pigment epithelium is not effective; neither support the macular visual cycle. Many biologic, practical, and ethical issues are associated with sourcing RPE cells for transplantation. RPE transplantation is not a viable therapy.[67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86]

Macular translocation has been advocated for subfoveal CNVM. One procedure uses vitrectomy, creation of a total retinal detachment, and a 360-degree retinotomy followed by retinal rotation. An alternate method, termed limited macular translocation, is based on retinal detachment creation and scleral imbrication or outpouching.[87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 41, 42, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 79, 80, 149, 150, 151, 36, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161]

Many eyes have been lost as a result of retinal translocation. Bleeding, retinal detachment, proliferative vitreoretinopathy (PVR), macular holes, new neovascular membranes, and good anatomical results without visual improvement are frequent complications of translocation.[162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173] Significant aniseikonia, high astigmatism, diplopia, enophthalmos, and ptosis are associated with limited macular translocation.[174, 175, 176, 177] Major cycloversion and diplopia are associated with retinal rotation methods.[178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188] Neither form of translocation has sufficient safety and efficacy to be indicated.

Consultations

In most cases, general ophthalmologists should consult retina specialists.

Diet

Eating spinach, kale, mustard greens, turnip greens, collard greens, nuts, and oily fish reduce the progression rate of patients with signs of early AMD. Berries and other plant-based diet elements rich in antioxidants are also probably effective. Patients may respond to suggesting a diet consisting of relative high quantities of richly colored vegetables and fruits, the so-called rainbow diet.

Activity

High blood pressure could theoretically result in bleeding from active neovascularization. Smoking increases the risk of AMD progression by 350-500%.

Pegaptanib (Macugen)

Clinical Context:  A selective VEGF antagonist that promotes vision stability and reduces visual acuity loss and progression to legal blindness. VEGF causes angiogenesis and increases vascular permeability and inflammation, all of which contribute to neovascularization in age-related wet macular degeneration. Macugen is much less effective than bevacizumab, aflibercept, or ranibizumab.

Class Summary

Reduces risk of visual loss similar to that seen with photodynamic therapy.

Further Outpatient Care

Postsubmacular surgery patients require a first postoperative day visit, followed by a 2- to 3-week visit. Thereafter, any time that the patient notes a change in the Amsler grid, a visit should be scheduled.

Further Inpatient Care

All medical and surgical treatments for choroidal neovascular membranes (CNVMs) can be performed in an outpatient setting.

Transfer

Retinal specialists should manage patients with CNVM.

Complications

Recurrent CNVMs occur in 25-50% of submacular surgery cases.

Cataracts occur frequently after vitreoretinal surgery.

Subretinal, suprachoroidal, and vitreous hemorrhage can occur after surgery.

Retinal detachment can occur after surgery.

Endophthalmitis can occur after any ocular surgery or intravitreal injection.

Steroid glaucoma occurs 20-30% of the time after intravitreal injection of Kenalog.

Prognosis

There is a 25-50% chance of recurrent CNVM after submacular surgery. Submacular hemorrhage is not uncommon after submacular surgery. Postoperative vision typically is limited by recurrences, damage to the RPE, and overlying retina.

Patient Education

Advise patients to use the Amsler grid to monitor their central fields daily.[189]

For excellent patient education resources, visit eMedicineHealth's Eye and Vision Center. Also, see eMedicineHealth's patient education article Macular Degeneration.

Author

Steve Charles, MD, Founder and CEO of Charles Retina Institute; Clinical Professor, Department of Ophthalmology, University of Tennessee College of Medicine

Disclosure: Received royalty and consulting fees for: Alcon Laboratories.

Specialty Editors

Simon K Law, MD, PharmD, Clinical Professor of Health Sciences, Department of Ophthalmology, Jules Stein Eye Institute, University of California, Los Angeles, David Geffen School of Medicine

Disclosure: Nothing to disclose.

Steve Charles, MD, Founder and CEO of Charles Retina Institute; Clinical Professor, Department of Ophthalmology, University of Tennessee College of Medicine

Disclosure: Received royalty and consulting fees for: Alcon Laboratories.

Chief Editor

Andrew A Dahl, MD, FACS, Assistant Professor of Surgery (Ophthalmology), New York College of Medicine (NYCOM); Director of Residency Ophthalmology Training, The Institute for Family Health and Mid-Hudson Family Practice Residency Program; Staff Ophthalmologist, Telluride Medical Center

Disclosure: Nothing to disclose.

Additional Contributors

V Al Pakalnis, MD, PhD, Professor of Ophthalmology, University of South Carolina School of Medicine; Chief of Ophthalmology, Dorn Veterans Affairs Medical Center

Disclosure: Nothing to disclose.

References

  1. la Cour M, Kiilgaard JF, Nissen MH. Age-related macular degeneration: epidemiology and optimal treatment. Drugs Aging. 2002. 19(2):101-33. [View Abstract]
  2. la Cour M, Nielsen NV, Larsen M, Haamann PH, Vinding T. [Age related macular degeneration. A widespread disease]. Ugeskr Laeger. 2001 Nov 12. 163(46):6396-400. [View Abstract]
  3. Verma L, Das T, Binder S, et al. New approaches in the management of choroidal neovascular membrane in age-related macular degeneration. Indian J Ophthalmol. 2000 Dec. 48(4):263-78. [View Abstract]
  4. Venkatesh P, Gupta RK, Verma L, Tewari HK. Evaluation of trans-scleral diode laser using diopexy probe for subfoveal choroidal neovascular membrane in age-related macular degeneration. J Clin Laser Med Surg. 2004 Apr. 22(2):91-7. [View Abstract]
  5. Soubrane G, Souied E, Haddad W, et al. Alternative therapies for choroidal neovessels resulting from age-related macular degeneration [in French]. J Fr Ophtalmol. 2003 Oct. 26(8):876-8. [View Abstract]
  6. Soubrane G, Kuhn D, Oubraham H, Quaranta M, Coscas G. [New therapies for the treatment of age-related macular degeneration]. J Soc Biol. 2001. 195(2):115-8. [View Abstract]
  7. Sickenberg M. Early detection, diagnosis and management of choroidal neovascularization in age-related macular degeneration: the role of ophthalmologists. Ophthalmologica. 2001 Jul-Aug. 215(4):247-53. [View Abstract]
  8. Seland JH. [Age-related macular degeneration]. Tidsskr Nor Laegeforen. 2004 Jan 8. 124(1):52-4. [View Abstract]
  9. Rumelt S, Kaiserman I, Rehany U, Ophir A, Pikkel J, Loewenstein A. Detachment of subfoveal choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol. 2002 Dec. 134(6):822-7. [View Abstract]
  10. Razavi S, Coscas G, Soubrane G. [Age related macular degeneration: a review of anti-angiogenic treatments]. J Fr Ophtalmol. 2002 Sep. 25(7):747-52. [View Abstract]
  11. Potocky M, Trnavec B. [Etiopathogenesis of age-related macular degeneration and present possibilities of treatment]. Bratisl Lek Listy. 2000. 101(4):231-3. [View Abstract]
  12. Oneill C, Jamison J, McCulloch D, Smith D. Age-related macular degeneration: cost-of-illness issues. Drugs Aging. 2001. 18(4):233-41. [View Abstract]
  13. Mohan KC, Shukla D, Namperumalsamy P, Kim R. Management of age-related macular degeneration. J Indian Med Assoc. 2003 Aug. 101(8):471-4, 476. [View Abstract]
  14. Mittra RA, Singerman LJ. Recent advances in the management of age-related macular degeneration. Optom Vis Sci. 2002 Apr. 79(4):218-24. [View Abstract]
  15. Mittra RA. New treatments for age-related macular degeneration. Minn Med. 2003 Apr. 86(4):40-6. [View Abstract]
  16. La Heij EC, Liem AT, Hendrikse F. [Age-related macular degeneration; therapeutic options]. Ned Tijdschr Geneeskd. 2001 Jul 21. 145(29):1390-7. [View Abstract]
  17. Korner-Stiefbold U. [Age-related macular degeneration (AMD)--therapeutic possibilities and new approaches]. Ther Umsch. 2001 Jan. 58(1):28-35. [View Abstract]
  18. Koh AH, Ang CL. Age-related macular degeneration: what's new. Ann Acad Med Singapore. 2002 May. 31(3):399-404. [View Abstract]
  19. Hunt DW, Margaron P. Status of therapies in development for the treatment of age-related macular degeneration. IDrugs. 2003 May. 6(5):464-9. [View Abstract]
  20. Hooper CY, Guymer RH. New treatments in age-related macular degeneration. Clin Experiment Ophthalmol. 2003 Oct. 31(5):376-91. [View Abstract]
  21. Frennesson C, Nilsson SE. [Age-related macular degeneration--new possibilities for prophylactic measures]. Lakartidningen. 2002 Aug 8. 99(32-33):3194-7. [View Abstract]
  22. Fong DS. Age-related macular degeneration: update for primary care. Am Fam Physician. 2000 May 15. 61(10):3035-42. [View Abstract]
  23. Donati G. [Current treatment of choroidal neovascularization in age-related macular degeneration]. J Fr Ophtalmol. 2002 Sep. 25(7):740-6. [View Abstract]
  24. Donati G. [Treatment according to "evidence-based medicine" of aged-related exudative age-related macular degeneration (laser photocoagulation and photodynamic therapy)]. Klin Monbl Augenheilkd. 2001 May. 218(5):313-5. [View Abstract]
  25. Coscas F, Stanescu D, Coscas G, Soubrane G. [Feeder vessel treatment of choroidal neovascularization in age-related macular degeneration]. J Fr Ophtalmol. 2003 Jun. 26(6):602-8. [View Abstract]
  26. Ciulla TA, Danis RP, Harris A. Age-related macular degeneration: a review of experimental treatments. Surv Ophthalmol. 1998 Sep-Oct. 43(2):134-46. [View Abstract]
  27. Akduman L, Del Priore LV, Desai VN, Olk RJ, Kaplan HJ. Perfusion of the subfoveal choriocapillaris affects visual recovery after submacular surgery in presumed ocular histoplasmosis syndrome. Am J Ophthalmol. 1997 Jan. 123(1):90-6. [View Abstract]
  28. Parodi MB, Da Pozzo S, Ravalico G. Angiographic features after photodynamic therapy for choroidal neovascularisation in age related macular degeneration and pathological myopia. Br J Ophthalmol. 2003 Feb. 87(2):177-83. [View Abstract]
  29. Wang X, Hu S. [A review of research actuality on age-related macular degeneration]. Yan Ke Xue Bao. 2001 Dec. 17(4):245-51. [View Abstract]
  30. Korte GE, Reppucci V, Henkind P. RPE destruction causes choriocapillary atrophy. Invest Ophthalmol Vis Sci. 1984 Oct. 25(10):1135-45. [View Abstract]
  31. Kuwabara T, Ishikawa Y, Kaiser-Kupfer MI. Experimental model of gyrate atrophy in animals. Ophthalmology. 1981 Apr. 88(4):331-5. [View Abstract]
  32. Flower RW, von Kerczek C, Zhu L, Ernest A, Eggleton C, Topoleski LD. Theoretical investigation of the role of choriocapillaris blood flow in treatment of subfoveal choroidal neovascularization associated with age-related macular degeneration. Am J Ophthalmol. 2001 Jul. 132(1):85-93. [View Abstract]
  33. Del Priore LV, Kaplan HJ, Hornbeck R, Jones Z, Swinn M. Retinal pigment epithelial debridement as a model for the pathogenesis and treatment of macular degeneration. Am J Ophthalmol. 1996 Nov. 122(5):629-43. [View Abstract]
  34. Apostol S. [Past, present, and future therapeutically options in age related macular degeneration]. Oftalmologia. 2002. 53(2):5-8. [View Abstract]
  35. Carstocea B, Gafencu O, Armegioiu M, et al. [Age related macular degeneration surgery]. Oftalmologia. 2002. 53(2):97-102. [View Abstract]
  36. Terasaki H, Miyake Y, Suzuki T, Nakamura M, Nagasaka T. Polypoidal choroidal vasculopathy treated with macular translocation: clinical pathological correlation. Br J Ophthalmol. 2002 Mar. 86(3):321-7. [View Abstract]
  37. Miskala PH, Hawkins BS, Mangione CM, et al. Responsiveness of the National Eye Institute Visual Function Questionnaire to changes in visual acuity: findings in patients with subfoveal choroidal neovascularization--SST Report No. 1. Arch Ophthalmol. 2003 Apr. 121(4):531-9. [View Abstract]
  38. Ergun E, Maar N, Radner W, Barbazetto I, Schmidt-Erfurth U, Stur M. Scotoma size and reading speed in patients with subfoveal occult choroidal neovascularization in age-related macular degeneration. Ophthalmology. 2003 Jan. 110(1):65-9. [View Abstract]
  39. Bermig J, Tylla H, Jochmann C, Nestler A, Wolf S. Angiographic findings in patients with exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2002 Mar. 240(3):169-75. [View Abstract]
  40. Torron Fernandez-Blanco C, Perez Olivan S, Melcon Sanchez-Friera B, Ferrer Novella E, Ruiz-Moreno O, Honrubia Lopez FM. [Dynamic angiography in age related macular degeneration]. Arch Soc Esp Oftalmol. 2002 Jul. 77(7):353-9. [View Abstract]
  41. Luke C, Aisenbrey S, Luke M, Marzella G, Bartz-Schmidt KU, Walter P. Electrophysiological changes after 360 degrees retinotomy and macular translocation for subfoveal choroidal neovascularisation in age related macular degeneration. Br J Ophthalmol. 2001 Aug. 85(8):928-32. [View Abstract]
  42. Luke C, Alteheld N, Aisenbrey S, et al. Electro-oculographic findings after 360 degrees retinotomy and macular translocation for subfoveal choroidal neovascularisation in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2003 Sep. 241(9):710-5. [View Abstract]
  43. Kaiser RS, Berger JW, Williams GA, et al. Variability in fluorescein angiography interpretation for photodynamic therapy in age-related macular degeneration. Retina. 2002 Dec. 22(6):683-90. [View Abstract]
  44. Cekiç O, Ohji M, KesercI B, et al. Evaluation of choroidal perfusion of the new central macular area by dilution analysis of indocyanine green angiography after macular translocation. Retina. 2004 Apr. 24(2):210-4. [View Abstract]
  45. Stoffelns BM. [Kinetics of indocyanine green (ICG) and clinical use for enhancement of transpupillary thermotherapy (TTT) in hypopigmented small choroidal melanomas]. Klin Monbl Augenheilkd. 2004 May. 221(5):374-8. [View Abstract]
  46. Kent DL, Fujii GY, Pieramici DJ, et al. Angiographic characteristics in patients undergoing macular translocation for subfoveal choroidal neovascularization secondary to age-related macular degeneration. Retina. 2003 Apr. 23(2):152-8. [View Abstract]
  47. Holz FG, Jorzik J, Schutt F, Flach U, Unnebrink K. Agreement among ophthalmologists in evaluating fluorescein angiograms in patients with neovascular age-related macular degeneration for photodynamic therapy eligibility (FLAP-study). Ophthalmology. 2003 Feb. 110(2):400-5. [View Abstract]
  48. Haddad WM, Coscas G, Soubrane G. Eligibility for treatment and angiographic features at the early stage of exudative age related macular degeneration. Br J Ophthalmol. 2002 Jun. 86(6):663-9. [View Abstract]
  49. Farah ME, Cardillo JA, Luzardo AC, Calucci D, Williams GA, Costa RA. Indocyanine green mediated photothrombosis for the management of predominantly classic choroidal neovascularisation caused by age related macular degeneration. Br J Ophthalmol. 2004 Aug. 88(8):1055-9. [View Abstract]
  50. Montero JA, Ruiz-Moreno JM, Tavolato M. Follow-up of age-related macular degeneration patients treated by photodynamic therapy with optical coherence tomography 3. Graefes Arch Clin Exp Ophthalmol. 2003 Oct. 241(10):797-802. [View Abstract]
  51. Witkin AJ, Vuong LN, Srinivasan VJ, et al. High-speed ultrahigh resolution optical coherence tomography before and after ranibizumab for age-related macular degeneration. Ophthalmology. 2009 May. 116(5):956-63. [View Abstract]
  52. Bereczki A, Toth J, Suveges I. Histological examination of the pigment epithelium-Bruch membrane-chorio-capillaris complex after macular translocation. Br J Ophthalmol. 2000 May. 84(5):550-1. [View Abstract]
  53. Castellarin AA, Sugino IK, Nasir M, Zarbin MA. Clinicopathological correlation of an excised choroidal neovascular membrane in pseudotumour cerebri. Br J Ophthalmol. 1997 Nov. 81(11):994-1000. [View Abstract]
  54. Mozaffarieh M, Sacu S, Wedrich A. The role of the carotenoids, lutein and zeaxanthin, in protecting against age-related macular degeneration: a review based on controversial evidence. Nutr J. 2003 Dec 11. 2:20. [View Abstract]
  55. Vadala M, Pece A, Cipolla S, et al. Is ranibizumab effective in stopping the loss of vision for choroidal neovascularisation in pathologic myopia? A long-term follow-up study. Br J Ophthalmol. 2011 May. 95(5):657-61. [View Abstract]
  56. Mones JM, Amselem L, Serrano A, Garcia M, Hijano M. Intravitreal ranibizumab for choroidal neovascularization secondary to pathologic myopia: 12-month results. Eye (Lond). 2009 Jun. 23(6):1275-80; quiz 1281. [View Abstract]
  57. Mitchell P, Korobelnik JF, Lanzetta P, et al. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol. 2009 May 20. [View Abstract]
  58. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006 Oct 5. 355(14):1419-31. [View Abstract]
  59. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006 Oct 5. 355(14):1432-44. [View Abstract]
  60. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology. 2009 Jan. 116(1):57-65.e5. [View Abstract]
  61. Klein KS, Walsh MK, Hassan TS, et al. Endophthalmitis after anti-VEGF injections. Ophthalmology. 2009 Jun. 116(6):1225.e1. [View Abstract]
  62. Thomas MA, Kaplan HJ. Surgical removal of subfoveal neovascularization in the presumed ocular histoplasmosis syndrome. Am J Ophthalmol. 1991 Jan 15. 111(1):1-7. [View Abstract]
  63. Schmidt JC, Rodrigues EB, Meyer CH, Kroll P. Is membrane extraction in cases of exudative age-related macular degeneration still up-to-date? A 4-year résumé. Ophthalmologica. 2003 Nov-Dec. 217(6):401-7. [View Abstract]
  64. Pollack JS, Del Priore LV, Smith ME, Feiner MA, Kaplan HJ. Postoperative abnormalities of the choriocapillaris in exudative age-related macular degeneration. Br J Ophthalmol. 1996 Apr. 80(4):314-8. [View Abstract]
  65. Castellarin AA, Nasir M, Sugino IK, Zarbin MA. Progressive presumed choriocapillaris atrophy after surgery for age-related macular degeneration. Retina. 1998. 18(2):143-9. [View Abstract]
  66. Zhang X, Bok D. Transplantation of retinal pigment epithelial cells and immune response in the subretinal space. Invest Ophthalmol Vis Sci. 1998 May. 39(6):1021-7. [View Abstract]
  67. Algvere PV, Berglin L, Gouras P, Sheng Y. Transplantation of fetal retinal pigment epithelium in age-related macular degeneration with subfoveal neovascularization. Graefes Arch Clin Exp Ophthalmol. 1994 Dec. 232(12):707-16. [View Abstract]
  68. Algvere PV, Berglin L, Gouras P, Sheng Y, Kopp ED. Transplantation of RPE in age-related macular degeneration: observations in disciform lesions and dry RPE atrophy. Graefes Arch Clin Exp Ophthalmol. 1997 Mar. 235(3):149-58. [View Abstract]
  69. Aramant RB, Seiler MJ, Ball SL. Successful cotransplantation of intact sheets of fetal retina with retinal pigment epithelium. Invest Ophthalmol Vis Sci. 1999 Jun. 40(7):1557-64. [View Abstract]
  70. Del Priore LV, Hornbeck R, Kaplan HJ, et al. Débridement of the pig retinal pigment epithelium in vivo. Arch Ophthalmol. 1995 Jul. 113(7):939-44. [View Abstract]
  71. Joussen AM. How complete is successful? "Autologous retinal pigment epithelium and choriod translocation in patients with exsudative age-related macular degeneration: a short-term follow-up" by Jan van Meurs and P.R. van Biesen. Graefes Arch Clin Exp Ophthalmol. 2003 Dec. 241(12):966-7. [View Abstract]
  72. Lane C, Boulton M, Marshall J. Transplantation of retinal pigment epithelium using a pars plana approach. Eye (Lond). 1989. 3 ( Pt 1):27-32. [View Abstract]
  73. Lappas A, Weinberger AW, Foerster AM, Kube T, Rezai KA, Kirchhof B. Iris pigment epithelial cell translocation in exudative age-related macular degeneration. A pilot study in patients. Graefes Arch Clin Exp Ophthalmol. 2000 Aug. 238(8):631-41. [View Abstract]
  74. Lavail MM, Li L, Turner JE, Yasumura D. Retinal pigment epithelial cell transplantation in RCS rats: normal metabolism in rescued photoreceptors. Exp Eye Res. 1992 Oct. 55(4):555-62. [View Abstract]
  75. Mueller-Jensen K, Machemer R, Azarnia R. Autotransplantation of retinal pigment epithelium in intravitreal diffusion chamber. Am J Ophthalmol. 1975 Sep. 80(3 Pt 2):530-7. [View Abstract]
  76. Peyman GA, Blinder KJ, Paris CL, Alturki W, Nelson NC Jr, Desai U. A technique for retinal pigment epithelium transplantation for age-related macular degeneration secondary to extensive subfoveal scarring. Ophthalmic Surg. 1991 Feb. 22(2):102-8. [View Abstract]
  77. Seaton AD, Turner JE. RPE transplants stabilize retinal vasculature and prevent neovascularization in the RCS rat. Invest Ophthalmol Vis Sci. 1992 Jan. 33(1):83-91. [View Abstract]
  78. Semkova I, Kreppel F, Welsandt G, et al. Autologous transplantation of genetically modified iris pigment epithelial cells: a promising concept for the treatment of age-related macular degeneration and other disorders of the eye. Proc Natl Acad Sci U S A. 2002 Oct 1. 99(20):13090-5. [View Abstract]
  79. Stanga PE, Kychenthal A, Fitzke FW, et al. Retinal pigment epithelium translocation and central visual function in age related macular degeneration: preliminary results. Int Ophthalmol. 2001. 23(4-6):297-307. [View Abstract]
  80. Stanga PE, Kychenthal A, Fitzke FW, et al. Retinal pigment epithelium translocation after choroidal neovascular membrane removal in age-related macular degeneration. Ophthalmology. 2002 Aug. 109(8):1492-8. [View Abstract]
  81. van Meurs JC, Van Den Biesen PR. Autologous retinal pigment epithelium and choroid translocation in patients with exudative age-related macular degeneration: short-term follow-up. Am J Ophthalmol. 2003 Oct. 136(4):688-95. [View Abstract]
  82. Binder S, Krebs I, Hilgers RD, et al. Outcome of transplantation of autologous retinal pigment epithelium in age-related macular degeneration: a prospective trial. Invest Ophthalmol Vis Sci. 2004 Nov. 45(11):4151-60. [View Abstract]
  83. Valentino TL, Kaplan HJ, Del Priore LV, Fang SR, Berger A, Silverman MS. Retinal pigment epithelial repopulation in monkeys after submacular surgery. Arch Ophthalmol. 1995 Jul. 113(7):932-8. [View Abstract]
  84. Yamaguchi K, Yamaguchi K, Young RW, et al. Vitreoretinal surgical technique for transplanting retinal pigment epithelium in rabbit retina. Jpn J Ophthalmol. 1992. 36(2):142-50. [View Abstract]
  85. Mueller-Jensen K, Mandelcorn MS. Membrane formation by autotransplanted retinal pigment epithelium. Mod Probl Ophthalmol. 1975. 15:228-34.
  86. Lappas A, Foerster AM, Weinberger AW, Coburger S, Schrage NF, Kirchhof B. Translocation of iris pigment epithelium in patients with exudative age-related macular degeneration: long-term results. Graefes Arch Clin Exp Ophthalmol. 2004 Aug. 242(8):638-47. [View Abstract]
  87. Abdel-Meguid A, Lappas A, Hartmann K, et al. One year follow up of macular translocation with 360 degree retinotomy in patients with age related macular degeneration. Br J Ophthalmol. 2003 May. 87(5):615-21. [View Abstract]
  88. Aisenbrey S, Bartz-Schmidt U. Macular translocation with 360-degree retinotomy for management of age-related macular degeneration with subfoveal choroidal neovascularization. Am J Ophthalmol. 2003 May. 135(5):748-9; author reply 749. [View Abstract]
  89. Aisenbrey S, Lafaut B, Szurman P, et al. [Macular translocation with 360 degree retinotomy in the treatment if exudative macular degeneration. Functional and angiographic results]. Ophthalmologe. 2002 Mar. 99(3):164-70. [View Abstract]
  90. Aisenbrey S, Lafaut BA, Szurman P, et al. Macular translocation with 360 degrees retinotomy for exudative age-related macular degeneration. Arch Ophthalmol. 2002 Apr. 120(4):451-9. [View Abstract]
  91. Akduman L, Karavellas MP, MacDonald JC, Olk RJ, Freeman WR. Macular translocation with retinotomy and retinal rotation for exudative age-related macular degeneration. Retina. 1999. 19(5):418-23. [View Abstract]
  92. Albini TA, Rao NA, Li A, Craft CM, Fujii GY, De Juan E Jr. Limited macular translocation: a clinicopathologic case report. Ophthalmology. 2004 Jun. 111(6):1209-14. [View Abstract]
  93. American Academy of Ophthalmology. Macular translocation. American Academy of Ophthalmology. Ophthalmology. 2000 May. 107(5):1015-8. [View Abstract]
  94. Au Eong KG, Pieramici DJ, Fujii GY, et al. Macular translocation: unifying concepts, terminology, and classification. Am J Ophthalmol. 2001 Feb. 131(2):244-53. [View Abstract]
  95. Benner JD, Meyer CH, Shirkey BL, Toth CA. Macular translocation with radial scleral ouffolding: experimental studies and initial human results. Graefes Arch Clin Exp Ophthalmol. 2001 Nov. 239(11):815-23. [View Abstract]
  96. Benner JD, Sunness JS, Ziegler MD, Soltanian J. Limited macular translocation for atrophic maculopathy. Arch Ophthalmol. 2002 May. 120(5):586-91. [View Abstract]
  97. Cahill MT, Freedman SF, Toth CA. Macular translocation with 360 degrees peripheral retinectomy for geographic atrophy. Arch Ophthalmol. 2003 Jan. 121(1):132-3. [View Abstract]
  98. Cekiç O, Keserci B, Ohji M, et al. Macular translocation surgery and retinal circulation times. Retina. 2004 Feb. 24(1):51-6. [View Abstract]
  99. Cekic O, Ohji M, Tano Y, Chang S. Continuous outflow devices for macular translocation with 360-degree retinotomy. Am J Ophthalmol. 2003 Feb. 135(2):241-3. [View Abstract]
  100. Chang AA, Tan W, Beaumont PE, Zeldovich A. Limited macular translocation for subfoveal choroidal neovascularization in age-related macular degeneration. Clin Experiment Ophthalmol. 2003 Apr. 31(2):103-9. [View Abstract]
  101. D'Amico DJ, Friberg TR. Limited inferior macular translocation for the treatment of subfoveal choroidal neovascularization secondary to age-related macular degeneration. Am J Ophthalmol. 2001 Aug. 132(2):289-90. [View Abstract]
  102. Deramo VA, Meyer CH, Toth CA. Successful macular translocation with temporary scleral infolding using absorbable sture. Retina. 2001. 21(4):304-11. [View Abstract]
  103. Dolezalova J, Rusnak S. [Macular translocation--first experience]. Cesk Slov Oftalmol. 2004 Jul. 60(4):239-47. [View Abstract]
  104. Eckardt C, Eckardt U. Macular translocation in nonexudative age-related macular degeneration. Retina. 2002 Dec. 22(6):786-94. [View Abstract]
  105. Eckardt C, Eckardt U, Groos S, Luciano L, Reale E. Macular translocation in a patient with adult-onset foveomacular vitelliform dystrophy with light- and electron-microscopic observations on the surgically removed subfoveal tissue. Graefes Arch Clin Exp Ophthalmol. 2004 Jun. 242(6):456-67. [View Abstract]
  106. Fang X, Hayashi A, Morimoto T, et al. Retinal changes after macular translocation with 360-degree retinotomy in monkey eyes. Am J Ophthalmol. 2004 Jun. 137(6):1034-41. [View Abstract]
  107. Faude F, Wendt S, Biedermann B, et al. Facilitation of artificial retinal detachment for macular translocation surgery tested in rabbit. Invest Ophthalmol Vis Sci. 2001 May. 42(6):1328-37. [View Abstract]
  108. Faude F, Wiedemann P, Reichenbach A. A "detachment infusion" for macular translocation surgery. Retina. 1999. 19(2):173-4. [View Abstract]
  109. Fujii GY, Au Eong KG, Humayun MS, de Juan E Jr. Limited macular translocation: current concepts. Ophthalmol Clin North Am. 2002 Dec. 15(4):425-36. [View Abstract]
  110. Fujii GY, de Juan E Jr, Au Eong KG, Harlan JB Jr. Effective nasal limited macular translocation. Am J Ophthalmol. 2001 Jul. 132(1):124-6. [View Abstract]
  111. Fujii GY, de Juan E Jr, Humayun MS, Chang TS. Limited macular translocation for the management of subfoveal choroidal neovascularization after photodynamic therapy. Am J Ophthalmol. 2003 Jan. 135(1):109-12. [View Abstract]
  112. Fujii GY, de Juan E Jr, Pieramici DJ, et al. Inferior limited macular translocation for subfoveal choroidal neovascularization secondary to age-related macular degeneration: 1-year visual outcome and recurrence report. Am J Ophthalmol. 2002 Jul. 134(1):69-74. [View Abstract]
  113. Fujii GY, de Juan E Jr, Sunness J, Humayun MS, Pieramici DJ, Chang TS. Patient selection for macular translocation surgery using the scanning laser ophthalmoscope. Ophthalmology. 2002 Sep. 109(9):1737-44. [View Abstract]
  114. Fujii GY, de Juan E, Thomas MA, Pieramici DJ, Humayun MS, Au Eong KG. Limited macular translocation for the management of subfoveal retinal pigment epithelial loss after submacular surgery. Am J Ophthalmol. 2001 Feb. 131(2):272-5. [View Abstract]
  115. Fujii GY, Humayun MS, Pieramici DJ, Schachat AP, Au Eong KG, de Juan E Jr. Initial experience of inferior limited macular translocation for subfoveal choroidal neovascularization resulting from causes other than age-related macular degeneration. Am J Ophthalmol. 2001 Jan. 131(1):90-100. [View Abstract]
  116. Glacet-Bernard A, Kuhn D, Coscas F, Coscas G, Soubrane G. [Translocation of the macula for retrofoveal choroidal neovascularization in age-related macular degeneration and severe myopia: first results]. J Fr Ophtalmol. 2000 Jun. 23(6):576-81. [View Abstract]
  117. Glacet-Bernard A, Simon P, Hamelin N, Coscas G, Soubrane G. Translocation of the macula for management of subfoveal choroidal neovascularization: comparison of results in age-related macular degeneration and degenerative myopia. Am J Ophthalmol. 2001 Jan. 131(1):78-89. [View Abstract]
  118. Gleadall R, Navarro VB, Dejuan E. Macular translocation--what our patients need to know. Insight. 2001 Jul-Sep. 26(3):73-6. [View Abstract]
  119. Grossniklaus HE, Brooks HL Jr, Sippy BD, Liu P. Retinal translocation and photodynamic therapy for age-related macular degeneration with classic choroidal neovascularization: a clinicopathologic case report. Retina. 2002 Dec. 22(6):818-24. [View Abstract]
  120. Gutierrez Amoros J, Gutierrez Amoros C. [Macular translocation in myopic patient wearing a phakic intraocular lens]. Arch Soc Esp Oftalmol. 2002 Feb. 77(2):99-101. [View Abstract]
  121. Güven D, Panzan CQ, Humayun MS, De Juan E Jr. Use of rotational sutures for limited retinal translocation: a new technique for superior limited macular translocation. Am J Ophthalmol. 2004 May. 137(5):901-7. [View Abstract]
  122. Haller JA, Hartranft CD, Fujii GY, Pieramici D, Humayun MS, de Juan E Jr. Limited macular translocation for neovascular maculopathy. Semin Ophthalmol. 2000 Jun. 15(2):81-7. [View Abstract]
  123. Hamelin N, Glacet-Bernard A, Brindeau C, Mimoun G, Coscas G, Soubrane G. Surgical treatment of subfoveal neovascularization in myopia: macular translocation vs surgical removal. Am J Ophthalmol. 2002 Apr. 133(4):530-6. [View Abstract]
  124. Ho CL. Macular translocation--an innovative treatment for macular degenerative diseases. Chang Gung Med J. 2000 Nov. 23(11):672-80. [View Abstract]
  125. Ichibe M, Imai K, Ohta M, Oya Y, Yoshizawa T, Abe H. Simultaneous translocation of the macula and underlying retinal pigment epithelium during macular translocation surgery in a patient with long standing myopic neovascular maculopathy. Br J Ophthalmol. 2003 Mar. 87(3):371-2. [View Abstract]
  126. Kamei M, Roth DB, Lewis H. Macular translocation with chorioscleral outfolding: an experimental study. Am J Ophthalmol. 2001 Aug. 132(2):149-55. [View Abstract]
  127. Kamei M, Tano Y, Yasuhara T, et al. Macular translocation with chorioscleral outfolding: 2-year results. Am J Ophthalmol. 2004 Oct. 138(4):574-81. [View Abstract]
  128. Koh SS, Arroyo J. Macular translocation with 360-degree retinotomy for treatment of exudative age-related macular degeneration. Int Ophthalmol Clin. 2004 Winter. 44(1):73-81. [View Abstract]
  129. Kubota A, Harino S, Ohji M, Tano Y. Modified technique to create retinal detachment during macular translocation surgery. Am J Ophthalmol. 2003 Jan. 135(1):105-6. [View Abstract]
  130. Landau K, Messmer E. [Translocation of the retina in senile macular degeneration]. Schweiz Med Wochenschr. 1999 Jan 12. 129(1-2):49-51. [View Abstract]
  131. Lewis H. Macular translocation with chorioscleral outfolding: a pilot clinical study. Am J Ophthalmol. 2001 Aug. 132(2):156-63. [View Abstract]
  132. Lewis H, Kaiser PK, Lewis S, Estafanous M. Macular translocation for subfoveal choroidal neovascularization in age-related macular degeneration: a prospective study. Am J Ophthalmol. 1999 Aug. 128(2):135-46. [View Abstract]
  133. Lin SB, Glaser BM, Gould D, Baudo TA, Lakhanpal RR, Murphy RP. Scleral outfolding for macular translocation. Am J Ophthalmol. 2000 Jul. 130(1):76-81. [View Abstract]
  134. Machemer R. Macular translocation. Am J Ophthalmol. 1998 May. 125(5):698-700. [View Abstract]
  135. McLeod D. Foveal translocation for exudative age related macular degeneration. Br J Ophthalmol. 2000 Apr. 84(4):344-5. [View Abstract]
  136. Morizane Y, Shiraga F, Takasu I, Yumiyama S, Okanouchi T, Ohtsuki H. Selection for inferior limited macular translocation on the basis of distance from the fovea to the inferior edge of the subfoveal choroidal neovascularization. Am J Ophthalmol. 2002 Jun. 133(6):848-50. [View Abstract]
  137. Ng EW, Fujii GY, Au Eong KG, et al. Macular translocation in patients with recurrent subfoveal choroidal neovascularization after laser photocoagulation for nonsubfoveal choroidal neovascularization. Ophthalmology. 2004 Oct. 111(10):1889-93. [View Abstract]
  138. Ohji M, Fujikado T, Kusaka S, et al. Comparison of three techniques of foveal translocation in patients with subfoveal choroidal neovascularization resulting from age-related macular degeneration. Am J Ophthalmol. 2001 Dec. 132(6):888-96. [View Abstract]
  139. Park CH, Toth CA. Macular translocation surgery with 360-degree peripheral retinectomy following ocular photodynamic therapy of choroidal neovascularization. Am J Ophthalmol. 2003 Nov. 136(5):830-5. [View Abstract]
  140. Pawlak D, Glacet-Bernard A, Papp M, Roquet W, Coscas G, Soubrane G. Limited macular translocation compared with photodynamic therapy in the management of subfoveal choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol. 2004 May. 137(5):880-7. [View Abstract]
  141. Pertile G, Claes C. Macular translocation with 360 degree retinotomy for management of age-related macular degeneration with subfoveal choroidal neovascularization. Am J Ophthalmol. 2002 Oct. 134(4):560-5. [View Abstract]
  142. Pieramici DJ, De Juan E Jr, Fujii GY, et al. Limited inferior macular translocation for the treatment of subfoveal choroidal neovascularization secondary to age-related macular degeneration. Am J Ophthalmol. 2000 Oct. 130(4):419-28. [View Abstract]
  143. Pieramici DJ, de Juna E Jr. Limited inferior macular translocation for the treatment of subfoveal choroidal neovascularization secondary to age-related macular degeneration. Am J Ophthalmol. 2001 Jul. 132(1):139-40. [View Abstract]
  144. Potter MJ, Chang TS, Lee AS, Rai S. Improvement in macular function after retinal translocation surgery in a patient with age-related macular degeneration. Am J Ophthalmol. 2000 Apr. 129(4):547-9. [View Abstract]
  145. Roig-Melo EA, Afaro DV 3rd, Heredia-Elizondo ML, et al. Macular translocation: histopathologic findings in swine eyes. Eur J Ophthalmol. 2000 Oct-Dec. 10(4):297-303. [View Abstract]
  146. Roth DB, Estafanous M, Lewis H. Macular translocation for subfoveal choroidal neovascularization in angioid streaks. Am J Ophthalmol. 2001 Mar. 131(3):390-2. [View Abstract]
  147. Sato M, Terasaki H, Ogino N, et al. Strabological findings after macular translocation surgery with 360 degrees retinotomy. Invest Ophthalmol Vis Sci. 2003 May. 44(5):1939-44. [View Abstract]
  148. Simon P, Glacet-Bernard A, Coscas G, Soubrane G. [Progression of choroidal neovascularization after macular translocation in age-related macular degeneration and degenerative myopia]. J Fr Ophtalmol. 2002 Sep. 25(7):694-700. [View Abstract]
  149. Sullivan P, Filsecker L, Sears J. Limited macular translocation with scleral retraction suture. Br J Ophthalmol. 2002 Apr. 86(4):434-9. [View Abstract]
  150. Terasaki H. Rescue of retinal function by macular translocation surgery in age-related macular degeneration and other diseases with subfoveal choroidal neovascularization. Nagoya J Med Sci. 2001 May. 64(1-2):1-9. [View Abstract]
  151. Terasaki H, Ishikawa K, Suzuki T, Nakamura M, Miyake K, Miyake Y. Morphologic and angiographic assessment of the macula after macular translocation surgery with 360 degrees retinotomy. Ophthalmology. 2003 Dec. 110(12):2403-8. [View Abstract]
  152. Terasaki H, Miyake Y, Suzuki T, et al. Change in full-field ERGs after macular translocation surgery with 360 degrees retinotomy. Invest Ophthalmol Vis Sci. 2002 Feb. 43(2):452-7. [View Abstract]
  153. Toth CA, Freedman SF. Macular translocation with 360-degree peripheral retinectomy impact of technique and surgical experience on visual outcomes. Retina. 2001. 21(4):293-303. [View Abstract]
  154. Wirostko WJ, Mittra RA, Rao PK, Borrillo JL, Dev S, Mieler WF. A combination light-pipe, soft-tipped suction, and infusion cannula instrument for macular translocation. Am J Ophthalmol. 2000 Apr. 129(4):549-51. [View Abstract]
  155. Mruthyunjaya P, Stinnett SS, Toth CA. Change in visual function after macular translocation with 360 degrees retinectomy for neovascular age-related macular degeneration. Ophthalmology. 2004 Sep. 111(9):1715-24. [View Abstract]
  156. Lai JC, Lapolice DJ, Stinnett SS, et al. Visual outcomes following macular translocation with 360-degree peripheral retinectomy. Arch Ophthalmol. 2002 Oct. 120(10):1317-24. [View Abstract]
  157. Kirchhof B. [Macular translocation. Improved prognosis for age-related macular degeneration]. Ophthalmologe. 2002 Mar. 99(3):143. [View Abstract]
  158. Ichibe M, Yoshizawa T, Funaki S, et al. Severe hypotony after macular translocation surgery with 360-degree retinotomy. Am J Ophthalmol. 2002 Jul. 134(1):139-41. [View Abstract]
  159. Fujikado T, Asonuma S, Ohji M, et al. Reading ability after macular translocation surgery with 360-degree retinotomy. Am J Ophthalmol. 2002 Dec. 134(6):849-56. [View Abstract]
  160. Fujii GY, De Juan E Jr, Zarbin MA, Humayun MS, Au Eong KG, Phillips S. Unintentional transplantation of autologous retinal pigment epithelium during limited macular translocation. Retina. 2001. 21(4):380-2. [View Abstract]
  161. Cekic O, Ohji M, Hayashi A, Fujikado T, Tano Y. Foveal translocation surgery in age-related macular degeneration. Lancet. 1999 Jul 24. 354(9175):340. [View Abstract]
  162. Jonas JB, Panda-Jonas S. Retinorhexis in macular translocation. Br J Ophthalmol. 2000 Oct. 84(10):1208. [View Abstract]
  163. Neugebauer A, Fricke J. [Sensory problems after macular translocation]. Ophthalmologe. 2002 Mar. 99(3):156-9. [View Abstract]
  164. Oyagi T, Fujikado T, Hosohata J, et al. Foveal sensitivity and fixation stability before and after macular translocation with 360-degree retinotomy. Retina. 2004 Aug. 24(4):548-55. [View Abstract]
  165. Sterker I, Wolf S, Wiedemann P. Strabological results in patients with macular translocation surgery and counterrotation of the globe as a secondary procedure. Strabismus. 2002 Jun. 10(2):111-7. [View Abstract]
  166. Terasaki H, Ishikawa K, Niwa Y, et al. Changes in focal macular ERGs after macular translocation surgery with 360 degrees retinotomy. Invest Ophthalmol Vis Sci. 2004 Feb. 45(2):567-73. [View Abstract]
  167. Toth CA, Lapolice DJ, Banks AD, Stinnett SS. Improvement in near visual function after macular translocation surgery with 360-degree peripheral retinectomy. Graefes Arch Clin Exp Ophthalmol. 2004 Jul. 242(7):541-8. [View Abstract]
  168. Vander JF. Macular translocation. Curr Opin Ophthalmol. 2000 Jun. 11(3):159-65. [View Abstract]
  169. Wolf S, Lappas A, Weinberger AW, Kirchhof B. Macular translocation for surgical management of subfoveal choroidal neovascularizations in patients with AMD: first results. Graefes Arch Clin Exp Ophthalmol. 1999 Jan. 237(1):51-7. [View Abstract]
  170. Zrenner E. Macular translocation in adult-onset vitelliform macular dystrophy: a therapy to be recommended?. Graefes Arch Clin Exp Ophthalmol. 2004 Jun. 242(6):453-5. [View Abstract]
  171. de Juan E Jr, Fujii GY. Limited macular translocation. Eye (Lond). 2001 Jun. 15:413-23. [View Abstract]
  172. de Juan E Jr, Vander JF. Effective macular translocation without scleral imbrication. Am J Ophthalmol. 1999 Sep. 128(3):380-2. [View Abstract]
  173. Au Eong KG, Fujii GY, Ng EW, Humayun MS, Pieramici DJ, de Juan E Jr. Transient formed visual hallucinations following macular translocation for subfoveal choroidal neovascularization secondary to age-related macular degeneration. Am J Ophthalmol. 2001 May. 131(5):664-6. [View Abstract]
  174. Fujii GY, Pieramici DJ, Humayun MS, et al. Complications associated with limited macular translocation. Am J Ophthalmol. 2000 Dec. 130(6):751-62. [View Abstract]
  175. Kadonosono K, Takeuchi S, Iwata S, Uchio E, Itoh N, Akura J. Macular fold after limited macular translocation treated with scleral shortening release and intravitreal gas. Am J Ophthalmol. 2001 Nov. 132(5):790-2. [View Abstract]
  176. Kim T, Krishnasamy S, Meyer CH, Toth CA. Induced corneal astigmatism after macular translocation surgery with scleral infolding. Ophthalmology. 2001 Jul. 108(7):1203-8. [View Abstract]
  177. Buffenn AN, de Juan E, Fujii G, Hunter DG. Diplopia after limited macular translocation surgery. J AAPOS. 2001 Dec. 5(6):388-94. [View Abstract]
  178. Akyurt A. [Cyclotropia and surgical treatment after macular translocation]. Klin Monbl Augenheilkd. 2002 Jan-Feb. 219(1-2):50-4. [View Abstract]
  179. Freedman SF, Gearinger MD, Enyedi LB, Holgado S, Toth CA. Measurement of ocular torsion after macular translocation: disc fovea angle and Maddox rod. J AAPOS. 2003 Apr. 7(2):103-7. [View Abstract]
  180. Freedman SF, Holgado S, Enyedi LB, Toth CA. Management of ocular torsion and diplopia after macular translocation for age-related macular degeneration: prospective clinical study. Am J Ophthalmol. 2003 Oct. 136(4):640-8. [View Abstract]
  181. Freedman SF, Rojas M, Toth CA. Strabismus surgery for large-angle cyclotorsion after macular translocation surgery. J AAPOS. 2002 Jun. 6(3):154-62. [View Abstract]
  182. Freedman SF, Seaber JH, Buckley EG, Enyedi LB, Toth CA. Combined superior oblique muscle recession and inferior oblique muscle advancement and transposition for cyclotorsion associated with macular translocation surgery. J AAPOS. 2000 Apr. 4(2):75-83. [View Abstract]
  183. Fricke J, Neugebauer A. [Surgical eye muscle counter-rotation after macular translocation]. Ophthalmologe. 2002 Mar. 99(3):160-3. [View Abstract]
  184. Fricke J, Neugebauer A, Nobis H, Bartz-Schmidt KU, Russmann W. Counterrotation of the globe in macular translocation. Graefes Arch Clin Exp Ophthalmol. 2000 Aug. 238(8):664-8. [View Abstract]
  185. Ohtsuki H, Shiraga F, Hasebe S, Kono R, Yamane T, Fujiwara H. Correction of cyclovertical strabismus induced by limited macular translocation in a case of age-related macular degeneration. Am J Ophthalmol. 2001 Feb. 131(2):270-2. [View Abstract]
  186. Ohtsuki H, Shiraga F, Morizane Y, Furuse T, Takasu I, Hasebe S. Transposition of the anterior superior oblique insertion as a treatment for excyclotorsion induced from limited macular translocation. Am J Ophthalmol. 2004 Jan. 137(1):125-34. [View Abstract]
  187. Seaber JH, Machemer R. Adaptation to monocular torsion after macular translocation. Graefes Arch Clin Exp Ophthalmol. 1997 Feb. 235(2):76-81. [View Abstract]
  188. Stappler T, Stanga P, Groenewald C, El Bably I, Wong D. Measurement of cyclotorsion in a patient following macular translocation surgery using a modified version of the Watzke-Allen test. Retina. 2003 Apr. 23(2):250-2. [View Abstract]
  189. Bressler NM. Early detection and treatment of neovascular age-related macular degeneration. J Am Board Fam Pract. 2002 Mar-Apr. 15(2):142-52. [View Abstract]
  190. American Academy of Ophthalmology. Photodynamic therapy with verteporfin for age-related macular degeneration. American Academy of Ophthalmology. Ophthalmology. 2000 Dec. 107(12):2314-7. [View Abstract]
  191. Armbrecht AM, Aspinall PA, Dhillon B. A prospective study of visual function and quality of life following PDT in patients with wet age related macular degeneration. Br J Ophthalmol. 2004 Oct. 88(10):1270-3. [View Abstract]
  192. Arnold JJ, Blinder KJ, Bressler NM, et al. Acute severe visual acuity decrease after photodynamic therapy with verteporfin: case reports from randomized clinical trials-TAP and VIP report no. 3. Am J Ophthalmol. 2004 Apr. 137(4):683-96. [View Abstract]
  193. Augustin AJ. [Photodynamic therapy with Vsudyne (Verteporfin)--an innovative therapy of age-related macular degeneration]. Krankenpfl J. 2000 Oct. 38(9-10):342-3. [View Abstract]
  194. Axer-Siegel R, Ehrlich R, Rosenblatt I, et al. Photodynamic therapy for occult choroidal neovascularization with pigment epithelium detachment in age-related macular degeneration. Arch Ophthalmol. 2004 Apr. 122(4):453-9. [View Abstract]
  195. Axer-Siegel R, Ehrlich R, Yassur Y, et al. Photodynamic therapy for age-related macular degeneration in a clinical setting: visual results and angiographic patterns. Am J Ophthalmol. 2004 Feb. 137(2):258-64. [View Abstract]
  196. Azab M, Benchaboune M, Blinder KJ, et al. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: meta-analysis of 2-year safety results in three randomized clinical trials: Treatment Of Age-Related Macular Degeneration With Photodynamic Therapy and Verteporfin In Photodynamic Therapy Study Report no. 4. Retina. 2004 Feb. 24(1):1-12. [View Abstract]
  197. Barbazetto I, Burdan A, Bressler NM, et al. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment--TAP and VIP report No. 2. Arch Ophthalmol. 2003 Sep. 121(9):1253-68. [View Abstract]
  198. Barnes RM, Gee L, Taylor S, Briggs MC, Harding SP. Outcomes in verteporfin photodynamic therapy for choroidal neovascularisation--'beyond the TAP study'. Eye (Lond). 2004 Aug. 18(8):809-13. [View Abstract]
  199. Battaglia Parodi M, Da Pozzo S. Hot spots after photodynamic therapy for choroidal neovascularization in age-related macular degeneration. Retina. 2002 Oct. 22(5):671-3. [View Abstract]
  200. Beck RW. Photodynamic therapy for age-related macular degeneration. Am J Ophthalmol. 2004 Sep. 138(3):513; author reply 513-4. [View Abstract]
  201. Bessler NM. Verteporfin therapy in age-related macular degeneration (VAM): an open-label multicenter photodynamic therapy study of 4,435 patients. Retina. 2004 Aug. 24(4):512-20. [View Abstract]
  202. Blinder KJ, Blumenkranz MS, Bressler NM, et al. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial--VIP report no. 3. Ophthalmology. 2003 Apr. 110(4):667-73. [View Abstract]
  203. Blumenkranz MS, Bressler NM, Bressler SB, et al. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials--TAP Report no. 5. Arch Ophthalmol. 2002 Oct. 120(10):1307-14. [View Abstract]
  204. Bressler NM. Age related macular degeneration. New hope for a common problem comes from photodynamic therapy. BMJ. 2000 Dec 9. 321(7274):1425-7. [View Abstract]
  205. Bressler NM. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol. 2001 Feb. 119(2):198-207. [View Abstract]
  206. Bressler NM, Arnold J, Benchaboune M, et al. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes-TAP report No. 3. Arch Ophthalmol. 2002 Nov. 120(11):1443-54. [View Abstract]
  207. Chan WM, Lam DS, Liu DT, Wong TH, Yuen KS. Photodynamic therapy for recurrent myopic choroidal neovascularisation after limited macular translocation surgery. Br J Ophthalmol. 2003 Sep. 87(9):1188-9. [View Abstract]
  208. Costa RA, Farah ME, Cardillo JA, Belfort R Jr. Photodynamic therapy with indocyanine green for occult subfoveal choroidal neovascularization caused by age-related macular degeneration. Curr Eye Res. 2001 Oct. 23(4):271-5. [View Abstract]
  209. Desmettre T, Cohen SY, Mordon S. [Photodynamic therapy and age-related macular degeneration in 2000]. J Fr Ophtalmol. 2001 Jan. 24(1):82-93. [View Abstract]
  210. Donati G, Kapetanios AD, Pournaras CJ. Principles of treatment of choroidal neovascularization with photodynamic therapy in age-related macular degeneration. Semin Ophthalmol. 1999 Mar. 14(1):2-10. [View Abstract]
  211. Eter N, Vogel A, Inhetvin-Hutter C, Spitznas M. Interval reduction of photodynamic therapy (PDT) in age-related macular degeneration (AMD) is not advantageous. A pilot project [in German]. Ophthalmologe. 2003 Apr. 100(4):314-7. [View Abstract]
  212. Fine SL. Photodynamic therapy with verteporfin is effective for selected patients with neovascular age-related macular degeneration. Arch Ophthalmol. 1999 Oct. 117(10):1400-2. [View Abstract]
  213. Foot B, Foy R, Chakravarthy U, Wormald R. Introduction of photodynamic therapy for the treatment of neovascular age-related macular degeneration: tracking a moving target. Eye (Lond). 2003 Jul. 17(5):583-6. [View Abstract]
  214. Franks W. Photodynamic therapy for age-related macular degeneration. Age Ageing. 2002 Jan. 31(1):5-6. [View Abstract]
  215. Gaynes BI, Fiscella RG. Safety of verteporfin for treatment of subfoveal choroidal neovascular membranes associated with age-related macular degeneration. Expert Opin Drug Saf. 2004 Jul. 3(4):345-61. [View Abstract]
  216. Hamon F, Goeminne P. Photodynamic therapy with verteporfin following transpupillary thermotherapy for CNV evolving from an initially occult to a predominantly classic form, in patients with AMD. Semin Ophthalmol. 2001 Dec. 16(4):223-32. [View Abstract]
  217. Hopley C, Salkeld G, Wang JJ, Mitchell P. Cost utility of screening and treatment for early age related macular degeneration with zinc and antioxidants. Br J Ophthalmol. 2004 Apr. 88(4):450-4. [View Abstract]
  218. Jaakkola A. [Photodynamic therapy of age-related macular degeneration]. Duodecim. 2002. 118(8):813-9. [View Abstract]
  219. Jin C, Ge J, Zhou S, et al. Photodynamic therapy for age-related macular degeneration. Yan Ke Xue Bao. 2004 Sep. 20(3):158-62. [View Abstract]
  220. Karacorlu M, Karacorlu S, Ozdemir H. Photodynamic therapy with delayed light application for the treatment of bilateral subfoveal choroidal neovascularization in age-related macular degeneration. Jpn J Ophthalmol. 2003 Nov-Dec. 47(6):595-8. [View Abstract]
  221. Kubicka-Trzaska A, Starzycka M. [Photodynamic therapy with indocyanine green for choroidal neovascularization caused by age-related macular degeneration--a preliminary record]. Klin Oczna. 2003. 105(6):351-4. [View Abstract]
  222. Messmer KJ, Abel SR. Verteporfin for age-related macular degeneration. Ann Pharmacother. 2001 Dec. 35(12):1593-8. [View Abstract]
  223. Miller JW, Schmidt-Erfurth U, Sickenberg M, et al. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study. Arch Ophthalmol. 1999 Sep. 117(9):1161-73. [View Abstract]
  224. Piermarocchi S, Lo Giudice G, Sartore M, et al. Photodynamic therapy increases the eligibility for feeder vessel treatment of choroidal neovascularization caused by age-related macular degeneration. Am J Ophthalmol. 2002 Apr. 133(4):572-5. [View Abstract]
  225. Rechtman E, Ciulla TA, Criswell MH, Pollack A, Harris A. An update on photodynamic therapy in age-related macular degeneration. Expert Opin Pharmacother. 2002 Jul. 3(7):931-8. [View Abstract]
  226. Rubin GS, Bressler NM. Effects of verteporfin therapy on contrast on sensitivity: Results From the Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) investigation-TAP report No 4. Retina. 2002 Oct. 22(5):536-44. [View Abstract]
  227. Sawa M, Chan WM, Ohji M, et al. Successful photodynamic therapy with verteporfin for recurrent choroidal neovascularization beneath the new fovea after macular translocation surgery with 360-degree retinotomy. Am J Ophthalmol. 2003 Sep. 136(3):560-3. [View Abstract]
  228. Schmidt-Erfurth U, Hasan T. Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. Surv Ophthalmol. 2000 Nov-Dec. 45(3):195-214. [View Abstract]
  229. Schmidt-Erfurth U, Miller JW, Sickenberg M, et al. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatments in a phase 1 and 2 study. Arch Ophthalmol. 1999 Sep. 117(9):1177-87. [View Abstract]
  230. Scorolli L, Scalinci SZ, Limoli PG, et al. [Photodynamic therapy for age related macular degeneration with and without antioxidants]. Can J Ophthalmol. 2002 Dec. 37(7):399-404. [View Abstract]
  231. Sharma S. Update in retina: photodynamic therapy for the treatment of subfoveal choroidal neovascularization secondary to age-related macular degeneration. Can J Ophthalmol. 2001 Feb. 36(1):7-10. [View Abstract]
  232. Sharma S, Bakal J, Oliver-Fernandez A, Blair J. Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization in age-related macular degeneration: results of an effectiveness study. Arch Ophthalmol. 2004 Jun. 122(6):853-6. [View Abstract]
  233. Sharma S, Brown GC, Brown MM, Hollands H, Shah GK. The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology. 2001 Nov. 108(11):2051-9. [View Abstract]
  234. Sivaprasad S, Hammond CJ, Jackson H. Photodynamic therapy for age-related macular degeneration. Eye (Lond). 2005 Sep. 19(9):1027-8. [View Abstract]
  235. Smith DH, Fenn P, Drummond M. Cost effectiveness of photodynamic therapy with verteporfin for age related macular degeneration: the UK case. Br J Ophthalmol. 2004 Sep. 88(9):1107-12. [View Abstract]
  236. Blinder KJ, Bradley S, Bressler NM, et al. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1. Am J Ophthalmol. 2003 Sep. 136(3):407-18. [View Abstract]
  237. van den Bergh H, Ballini JP, Sickenberg M. On the selectivity of photodynamic therapy of choroidal neovascularization associated with age-related macular degeneration. J Fr Ophtalmol. 2004 Jan. 27(1):75-8. [View Abstract]
  238. van den Bergh H. Photodynamic therapy of age-related macular degeneration: History and principles. Semin Ophthalmol. 2001 Dec. 16(4):181-200. [View Abstract]
  239. Yassur Y, Weinberger D, Goldstein M, Loewenstein A. [Photodynamic therapy in age-related macular degeneration]. Harefuah. 2000 Sep. 139(5-6):220-3. [View Abstract]
  240. Wykrota H, Gierek-Lapinska A. [Photodynamic therapy in age-related macular degeneration--results of one year observation]. Klin Oczna. 2002. 104(3-4):239-43. [View Abstract]
  241. Wu L, Murphy RP. Photodynamic therapy: a new approach to the treatment of choroidal neovascularization secondary to age-related macular degeneration. Curr Opin Ophthalmol. 1999 Jun. 10(3):217-20. [View Abstract]
  242. Wormald R, Evans J, Smeeth L, Henshaw K. Photodynamic therapy for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2003. CD002030. [View Abstract]
  243. Wormald R, Evans J, Smeeth L, Henshaw K. Photodynamic therapy for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2001. CD002030. [View Abstract]
  244. Wormald R, Evans J, Smeeth L. Photodynamic therapy for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2000. CD002030. [View Abstract]
  245. Wenkstern A, Stokes J. Photodynamic therapy in age-related macular degeneration: missing information. Age Ageing. 2003 May. 32(3):357-9. [View Abstract]
  246. Verteporfin Roundtable 2000 and 2001 Participants. Guidelines for using verteporfin (visudyne) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes. Retina. 2002 Feb. 22(1):6-18. [View Abstract]
  247. Torron Fernandez-Blanco C, Perez Olivan S, et al. [Photodynamic therapy for choroidal neovascularization not caused by age related macular degeneration or pathologic myopia]. Arch Soc Esp Oftalmol. 2003 Sep. 78(9):471-6. [View Abstract]
  248. Tholen AM, Bernasconi PP, Fierz AB, Messmer EP. [Reading ability after photodynamic therapy (PDT) for age-related macular degeneration (AMD) and for high myopia]. Ophthalmologe. 2003 Jan. 100(1):28-32. [View Abstract]
  249. Sternberg P Jr, Lewis H. Photodynamic therapy for age-related macular degeneration: a candid appraisal. Am J Ophthalmol. 2004 Mar. 137(3):483-5. [View Abstract]
  250. Soubrane G, Kuhn D, Coscas G. [Indications for photodynamic therapy in age-related macular degeneration]. J Fr Ophtalmol. 2004 Jan. 27(1):79-80. [View Abstract]
  251. Soubrane G, Bressler NM. Treatment of subfoveal choroidal neovascularisation in age related macular degeneration: focus on clinical application of verteporfin photodynamic therapy. Br J Ophthalmol. 2001 Apr. 85(4):483-95. [View Abstract]
  252. Samkoe KS, Cramb DT. Application of an ex ovo chicken chorioallantoic membrane model for two-photon excitation photodynamic therapy of age-related macular degeneration. J Biomed Opt. 2003 Jul. 8(3):410-7. [View Abstract]
  253. Ruiz-Moreno JM, Montero JA. Sequential combined therapy for treatment of choroidal neovascularization in age-related macular degeneration: photodynamic therapy and thermal laser photocoagulation. Eur J Ophthalmol. 2003 Oct. 13(8):681-6. [View Abstract]
  254. Theodossiadis GP, Panagiotidis D, Georgalas IG, Moschos M, Theodossiadis PG. Retinal hemorrhage after photodynamic therapy in patients with subfoveal choroidal neovascularization caused by age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2003 Jan. 241(1):13-8. [View Abstract]
  255. Porter T, Nesbitt P. Psychosocial implications of clinical trials on patients with age-related macular degeneration and pathologic myopia as seen in the photodynamic therapy trials. Insight. 2001 Apr. 26(2):40-3. [View Abstract]
  256. Meads C, Salas C, Roberts T, Moore D, Fry-Smith A, Hyde C. Clinical effectiveness and cost-utility of photodynamic therapy for wet age-related macular degeneration: a systematic review and economic evaluation. Health Technol Assess. 2003. 7(9):v-vi, 1-98. [View Abstract]
  257. Mandal N, Chisholm IH. Identifying the proportion of age related macular degeneration patients who would benefit from photodynamic therapy with verteporfin (Visudyne). Br J Ophthalmol. 2002 Jan. 86(1):118-9. [View Abstract]
  258. Japanese Age-Related Macular Degeneration Trial (JAT) Study Group. Japanese age-related macular degeneration trial: 1-year results of photodynamic therapy with verteporfin in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Am J Ophthalmol. 2003 Dec. 136(6):1049-61. [View Abstract]
  259. Isola V, Pece A, Brancato R. Circulatory changes in the choroidal vasculature after verteporfin-based photodynamic therapy for choroidal neovascularization in age-related macular degeneration. Retina. 2004 Aug. 24(4):618-20. [View Abstract]
  260. Hopley C, Salkeld G, Mitchell P. Cost utility of photodynamic therapy for predominantly classic neovascular age related macular degeneration. Br J Ophthalmol. 2004 Aug. 88(8):982-7. [View Abstract]
  261. Greiner RA. Cost of care for patients with age-related macular degeneration in Switzerland and cost-effectiveness of treatment with verteporfin therapy. Semin Ophthalmol. 2001 Dec. 16(4):218-22. [View Abstract]
  262. Gierek-Lapinska A, Wykrota H, Trzciakowski K. [New methods of treatment of age-related macular degeneration. Photodynamic therapy. Part I]. Klin Oczna. 2002. 104(3-4):276-82. [View Abstract]
  263. Ghazi NG, Jabbour NM, De La Cruz ZC, Green WR. Clinicopathologic studies of age-related macular degeneration with classic subfoveal choroidal neovascularization treated with photodynamic therapy. Retina. 2001. 21(5):478-86. [View Abstract]
  264. Cohen SY, Bulik A, Tadayoni R, Quentel G. Visual hallucinations and Charles Bonnet syndrome after photodynamic therapy for age related macular degeneration. Br J Ophthalmol. 2003 Aug. 87(8):977-9. [View Abstract]
  265. Bressler NM. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2. Am J Ophthalmol. 2002 Jan. 133(1):168-9. [View Abstract]
  266. Bressler SB, Pieramici DJ, Koester JM, Bressler NM. Natural history of minimally classic subfoveal choroidal neovascular lesions in the treatment of age-related macular degeneration with photodynamic therapy (TAP) investigation: outcomes potentially relevant to management--TAP report No. 6. Arch Ophthalmol. 2004 Mar. 122(3):325-9. [View Abstract]
  267. TAP Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch Ophthalmol. 1999 Oct. 117(10):1329-45. [View Abstract]
  268. Ruiz-Oliva F, Cortés J. Verteporfin in Photodynamic Therapy (VIP) Study group. Ophthalmology. 2002 Jun. 109(6):1043; author reply 1043-4. [View Abstract]
  269. Verteporfin in Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial--VIP report no. 1. Ophthalmology. 2001 May. 108(5):841-52. [View Abstract]
  270. Verteporfin In Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynamic therapy report 2. Am J Ophthalmol. 2001 May. 131(5):541-60. [View Abstract]
  271. Rechtman E, Danis RP, Pratt LM, Harris A. Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularisation in age related macular degeneration. Br J Ophthalmol. 2004 Mar. 88(3):344-7. [View Abstract]
  272. Ahuja RM, Benner JD, Schwartz JC, Butler JW, Steidl SM. Efficacy of transpupillary thermotherapy (TTT) in the treatment of occult subfoveal choroidal neovascularization in age-related macular degeneration. Semin Ophthalmol. 2001 Jun. 16(2):81-5. [View Abstract]
  273. Auer C, Tao Tran V, Herbort CP. Transpupillary thermotherapy for occult subfoveal neovessels in age-related macular degeneration: importance of patient pigmentation for the determination of laser settings. Klin Monbl Augenheilkd. 2002 Apr. 219(4):250-3. [View Abstract]
  274. Desmettre T, Maurage CA, Mordon S. Transpupillary thermotherapy (TTT) with short duration laser exposures induce heat shock protein (HSP) hyperexpression on choroidoretinal layers. Lasers Surg Med. 2003. 33(2):102-7. [View Abstract]
  275. Friberg TR, Pandya A, Nazari K. Transpupillary thermotherapy (TTT) for age-related macular degeneration. Semin Ophthalmol. 2001 Jun. 16(2):70-80. [View Abstract]
  276. Mueller AJ, Ulbig M, Kampik A. TTT for occult CNV: check the power!. Br J Ophthalmol. 2002 Oct. 86(10):1194. [View Abstract]
  277. Newsom R. TTT and CNV. Br J Ophthalmol. 2001 Oct. 85(10):1268-9. [View Abstract]
  278. Newsom RS, McAlister JC, Saeed M, McHugh JD. Transpupillary thermotherapy (TTT) for the treatment of choroidal neovascularisation. Br J Ophthalmol. 2001 Feb. 85(2):173-8. [View Abstract]
  279. Park CH, Duker JS, Mainster MA, Puliafito CA, Reichel E. Transpupillary thermotherapy (TTT) of occult choroidal neovascularization: a retrospective, noncomparative case series of fifty-seven eyes. Semin Ophthalmol. 2001 Jun. 16(2):66-9. [View Abstract]
  280. Verma L, Sinha A, Nainiwal S, Tewari HK. Transpupillary thermo therapy for the treatment of choroidal neovascularisation secondary to age related macular degeneration in Indian eyes. Indian J Ophthalmol. 2004 Mar. 52(1):86-7; author reply 87. [View Abstract]
  281. Verma L, Tewari HK, Nainiwal S, Ravindranathan J. Transpupillary thermotherapy in subfoveal choroidal neovascular membrane secondary to age-related macular degeneration. Indian J Ophthalmol. 2004 Mar. 52(1):35-40. [View Abstract]
  282. Ciulla TA, Danis RP, Criswell M, Pratt LM. Changing therapeutic paradigms for exudative age-related macular degeneration: antiangiogenic agents and photodynamic therapy. Expert Opin Investig Drugs. 1999 Dec. 8(12):2173-2182. [View Abstract]
  283. Eyetech Study Group. Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results. Ophthalmology. 2003 May. 110(5):979-86. [View Abstract]
  284. Ciulla TA, Danis RP, Klein SB, et al. Proton therapy for exudative age-related macular degeneration: a randomized, sham-controlled clinical trial. Am J Ophthalmol. 2002 Dec. 134(6):905-6. [View Abstract]
  285. Sivagnanavel V, Evans JR, Ockrim Z, Chong V. Radiotherapy for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2004 Oct 18. CD004004. [View Abstract]
  286. Ergun E, Stur M. TTT and CNV. Br J Ophthalmol. 2001 Aug. 85(8):1013. [View Abstract]
  287. Hammerstein W, Gebauer HJ. [Familial nystagmus and hypoplasia of the macular in reciprocal, balanced translocation 5/16]. Fortschr Ophthalmol. 1989. 86(6):718-21. [View Abstract]
  288. Takeuchi M, Itagaki T, Takahashi K, Ohkuma H, Uyama M. [Changes in the intermediate stage of retinal degeneration after intravitreal injection of ornithine]. Nippon Ganka Gakkai Zasshi. 1993 Jan. 97(1):17-28. [View Abstract]
  289. Congdon NG, Friedman DS, Lietman T. Important causes of visual impairment in the world today. JAMA. 2003 Oct 15. 290 (15):2057-60. [View Abstract]
  290. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Macular Photocoagulation Study Group. Arch Ophthalmol. 1991 Sep. 109 (9):1220-31. [View Abstract]
  291. Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch Ophthalmol. 1999 Oct. 117 (10):1329-45. [View Abstract]
  292. Verteporfin In Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynamic therapy report 2. Am J Ophthalmol. 2001 May. 131 (5):541-60. [View Abstract]
  293. Yancopoulos GD. Clinical application of therapies targeting VEGF. Cell. 2010 Oct 1. 143 (1):13-6. [View Abstract]
  294. Ferrara N. VEGF-A: a critical regulator of blood vessel growth. Eur Cytokine Netw. 2009 Dec. 20 (4):158-63. [View Abstract]
  295. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006 Oct 5. 355 (14):1419-31. [View Abstract]
  296. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006 Oct 5. 355 (14):1432-44. [View Abstract]
  297. Schmidt-Erfurth U, Eldem B, Guymer R, Korobelnik JF, Schlingemann RO, Axer-Siegel R, et al. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology. 2011 May. 118 (5):831-9. [View Abstract]
  298. Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol. 2008 Feb. 145 (2):239-248. [View Abstract]
  299. Boyer DS, Heier JS, Brown DM, Francom SF, Ianchulev T, Rubio RG. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology. 2009 Sep. 116 (9):1731-9. [View Abstract]
  300. Singer MA, Awh CC, Sadda S, Freeman WR, Antoszyk AN, Wong P, et al. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology. 2012 Jun. 119 (6):1175-83. [View Abstract]
  301. CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011 May 19. 364 (20):1897-908. [View Abstract]
  302. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012 Jul. 119 (7):1388-98. [View Abstract]
  303. IVAN Study Investigators, Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012 Jul. 119 (7):1399-411. [View Abstract]
  304. Economides AN, Carpenter LR, Rudge JS, Wong V, Koehler-Stec EM, Hartnett C, et al. Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat Med. 2003 Jan. 9 (1):47-52. [View Abstract]
  305. Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A. 2002 Aug 20. 99 (17):11393-8. [View Abstract]
  306. Heier JS, Boyer D, Nguyen QD, Marcus D, Roth DB, Yancopoulos G, et al. The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing. Ophthalmology. 2011 Jun. 118 (6):1098-106. [View Abstract]
  307. Stewart MW, Rosenfeld PJ. Predicted biological activity of intravitreal VEGF Trap. Br J Ophthalmol. 2008 May. 92 (5):667-8. [View Abstract]
  308. Brown DM, Heier JS, Ciulla T, Benz M, Abraham P, Yancopoulos G, et al. Primary endpoint results of a phase II study of vascular endothelial growth factor trap-eye in wet age-related macular degeneration. Ophthalmology. 2011 Jun. 118 (6):1089-97. [View Abstract]